Newark, NJ, March 19, 2026 (GLOBE NEWSWIRE) -- Genie Energy, Ltd. (NYSE: GNE), a leading retail energy and renewable energy solutions provider, today provided an update on its fourth quarter and full ...

Newark, NJ, March 19, 2026 (GLOBE NEWSWIRE) -- Genie Energy, Ltd. (NYSE: GNE), a leading retail energy and renewable energy solutions provider, today provided an update on its fourth quarter and full ...

HAMPTON — The recount stretched through the day, but by 5:30 p.m. Tuesday, incumbent Selectman Chuck Rage had secured his third term on the board, holding his seat by a margin of four votes. Hampton ...

SEABROOK — Harold Eaton was elected to his second term on the Seabrook Select Board, defeating his challenger, Rick "Bubba" Titus, in the March 10 election. Eaton received 844 votes to Titus' 224. "I ...

AI data centers can operate without using peak power continuously, according to the results of a UK trial, a finding that could have implications for electricity systems worldwide. Grids from the US ...

REDMOND, Ore., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Expion360 Inc. (XPON) (Nasdaq: XPON) (“Expion360” or the “Company”), an industry leader in lithium-ion battery power storage solutions, today announced ...

Pranay Parab is an independent tech journalist based in Mumbai, India. He covers tech for Lifehacker, and specializes in tutorials and in-depth features. It's not just you. Google Search has become ...

Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. Preliminary Fourth Quarter 2025 Financial Results: ...

The MarketWatch News Department was not involved in the creation of this content. CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune ...

PLEASANTON, Calif., Jan. 11, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth ...

Using less ipilimumab appears to make melanoma immunotherapy both safer and more effective, with dramatically better response and survival outcomes. The findings suggest that reducing side effects may ...